431 related articles for article (PubMed ID: 28789624)
1. Hedgehog inhibitor sonidegib potentiates
Spetz J; Langen B; Rudqvist N; Parris TZ; Helou K; Nilsson O; Forssell-Aronsson E
BMC Cancer; 2017 Aug; 17(1):528. PubMed ID: 28789624
[TBL] [Abstract][Full Text] [Related]
2. Time-dependent transcriptional response of GOT1 human small intestine neuroendocrine tumor after
Spetz J; Rudqvist N; Langen B; Parris TZ; Dalmo J; Schüler E; Wängberg B; Nilsson O; Helou K; Forssell-Aronsson E
Nucl Med Biol; 2018 May; 60():11-18. PubMed ID: 29502008
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional effects of
Spetz J; Langen B; Rudqvist NP; Parris TZ; Shubbar E; Dalmo J; Wängberg B; Nilsson O; Helou K; Forssell-Aronsson E
EJNMMI Res; 2019 Mar; 9(1):28. PubMed ID: 30895393
[TBL] [Abstract][Full Text] [Related]
4. Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1.
Swärd C; Bernhardt P; Johanson V; Schmitt A; Ahlman H; Stridsberg M; Forssell-Aronsson E; Nilsson O; Kölby L
Cancer Biother Radiopharm; 2008 Feb; 23(1):114-20. PubMed ID: 18298335
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
[TBL] [Abstract][Full Text] [Related]
6. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM
Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274
[TBL] [Abstract][Full Text] [Related]
7. Recombinant α
Andersson CK; Shubbar E; Schüler E; Åkerström B; Gram M; Forssell-Aronsson EB
J Nucl Med; 2019 Nov; 60(11):1600-1604. PubMed ID: 30926650
[TBL] [Abstract][Full Text] [Related]
8. NAMPT Inhibitor GMX1778 Enhances the Efficacy of 177Lu-DOTATATE Treatment of Neuroendocrine Tumors.
Elf AK; Bernhardt P; Hofving T; Arvidsson Y; Forssell-Aronsson E; Wängberg B; Nilsson O; Johanson V
J Nucl Med; 2017 Feb; 58(2):288-292. PubMed ID: 27688470
[TBL] [Abstract][Full Text] [Related]
9. Peptide Receptor Radionuclide Therapy with
Cullinane C; Jeffery CM; Roselt PD; van Dam EM; Jackson S; Kuan K; Jackson P; Binns D; van Zuylekom J; Harris MJ; Hicks RJ; Donnelly PS
J Nucl Med; 2020 Dec; 61(12):1800-1805. PubMed ID: 32414949
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
Brechbiel J; Miller-Moslin K; Adjei AA
Cancer Treat Rev; 2014 Jul; 40(6):750-9. PubMed ID: 24613036
[TBL] [Abstract][Full Text] [Related]
11. Effects of treatment with (177)Lu-DOTA-Tyr(3)-octreotate on uptake of subsequent injection in carcinoid-bearing nude mice.
Bernhardt P; Oddstig J; Kölby L; Nilsson O; Ahlman H; Forssell-Aronsson E
Cancer Biother Radiopharm; 2007 Oct; 22(5):644-53. PubMed ID: 17979567
[TBL] [Abstract][Full Text] [Related]
12. Priming increases the anti-tumor effect and therapeutic window of
Dalmo J; Spetz J; Montelius M; Langen B; Arvidsson Y; Johansson H; Parris TZ; Helou K; Wängberg B; Nilsson O; Ljungberg M; Forssell-Aronsson E
EJNMMI Res; 2017 Dec; 7(1):6. PubMed ID: 28097640
[TBL] [Abstract][Full Text] [Related]
13. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
14. Neuroblastoma xenograft models demonstrate the therapeutic potential of
Romiani A; Spetz J; Shubbar E; Lind DE; Hallberg B; Palmer RH; Forssell-Aronsson E
BMC Cancer; 2021 Aug; 21(1):950. PubMed ID: 34433438
[TBL] [Abstract][Full Text] [Related]
15. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
16. Hyperfractionated Treatment with
Elvborn M; Shubbar E; Forssell-Aronsson E
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008397
[TBL] [Abstract][Full Text] [Related]
17. Co-administration with A1M does not influence apoptotic response of
Rassol N; Andersson C; Pettersson D; Al-Awar A; Shubbar E; Kovács A; Åkerström B; Gram M; Helou K; Forssell-Aronsson E
Sci Rep; 2023 Apr; 13(1):6417. PubMed ID: 37076494
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor metastatic progression.
Djukom C; Porro LJ; Mrazek A; Townsend CM; Hellmich MR; Chao C
Pancreas; 2014 Jan; 43(1):88-92. PubMed ID: 24263107
[TBL] [Abstract][Full Text] [Related]
19. 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition.
Hofving T; Sandblom V; Arvidsson Y; Shubbar E; Altiparmak G; Swanpalmer J; Almobarak B; Elf AK; Johanson V; Elias E; Kristiansson E; Forssell-Aronsson E; Nilsson O
Endocr Relat Cancer; 2019 Apr; 26(4):437-449. PubMed ID: 30730850
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
